Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Registration Number
- NCT05536700
- Brief Summary
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while M-protein is a widely accepted biomarker used for multiple myeloma (MM) diagnose. Detecting MRD by monitoring M-protein using mass spectrometry (MS) is promising due to its high analytical sensitivity. To evaluate the correlation between MS-MRD and overall disease burden, over 60 patients with 500+ samples were identified for this study. The M-protein sequence and the patient-specific M-protein peptides of each patient were obtained by de novo protein sequencing platform using the diagnostic serum (\> 30g/L). The follow- up samples were then measured by a parallel reaction monitoring (PRM) assay.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 67
Subjects with available baseline and sequential serum samples.
Subjects without baseline and sequential serum samples.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quantitative measurement of M protein From June 6, 2022 to December 31, 2022 Detecting the M protein concentration and its dynamic change curve
- Secondary Outcome Measures
Name Time Method sequence detection of M protein From December 31, 2021 to May 31, 2022 Detecting the M protein sequence in each person
Trial Locations
- Locations (1)
InsituteHBDH
🇨🇳Tianjin, China